There is a need for multiplexed assay technologies that enable diagnostics and detailed characterization of rheumatoid arthritis. In this project we plan to discover new rheumatoid arthritis biomarkers and implement them in a panel of multiplexed assays. We propose a novel approach that offers significant advances over existing methods, including the ability to rapidly develop, validate, and implement highly multiplexed, high- performance assays. If successful, our long-term goal is to transfer these new assays to the clinic as valuable new tools for high sensitivity diagnostics and treatment decision- making.

Public Health Relevance

We are developing multiplexed assays for rheumatoid arthritis. The assays will be useful for earlier disease detection, classification, and monitoring response to treatment. If successful, this project will improve rheumatoid arthritis diagnosis and aid therapeutic decision-making.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AR067113-01A1
Application #
8833870
Study Section
Special Emphasis Panel (ZRG1-IMST-G (10))
Program Officer
Mao, Su-Yau
Project Start
2014-09-18
Project End
2015-08-31
Budget Start
2014-09-18
Budget End
2015-08-31
Support Year
1
Fiscal Year
2014
Total Cost
$224,688
Indirect Cost
Name
Prognosys Biosciences, Inc.
Department
Type
DUNS #
170943737
City
San Diego
State
CA
Country
United States
Zip Code
92121